Clofibrate And Niacin In Coronary Heart Disease

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 2840
Sex Male
Age Range 30-44, 45-64
Notes for this study:
In a study randomizing subjects to one of six groups, one of which was 3g of niacin daily (an active control of clofibrate), in men between the ages of 30-64 who experienced at least one myocardial infarction, supplementation of niacin reduced cholesterol and triglycerides relative to placebo throughout the study period and for five years followup.

Niacin appeared to reduce overall cardiovascular events, but did not reduce overall mortality relative to placebo.

Niacin was associated with a higher dropout rate than other groups, thought to be due to the niacin flush.

Full details on all 2 studies are available to Examine Plus members.

Already a member? Login now to access.